Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma.

George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM.

J Hematol Oncol. 2019 Jul 24;12(1):80. doi: 10.1186/s13045-019-0768-8.

2.

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.

Aiken R, Axelson M, Harmenberg J, Klockare M, Larsson O, Wassberg C.

Oncotarget. 2017 Sep 6;8(46):81501-81510. doi: 10.18632/oncotarget.20662. eCollection 2017 Oct 6.

3.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.

4.

Circulating androgens and SHBG during the normal menstrual cycle in two ethnic populations.

Rezaii T, Gustafsson TP, Axelson M, Zamani L, Ernberg M, Hirschberg AL, Carlström KA.

Scand J Clin Lab Invest. 2017 May;77(3):184-189. doi: 10.1080/00365513.2017.1286685. Epub 2017 Mar 1.

PMID:
28276724
5.

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Ekman S, Harmenberg J, Frödin JE, Bergström S, Wassberg C, Eksborg S, Larsson O, Axelson M, Jerling M, Abrahmsen L, Hedlund Å, Alvfors C, Ståhl B, Bergqvist M.

Acta Oncol. 2016;55(2):140-8. doi: 10.3109/0284186X.2015.1049290. Epub 2015 Jul 10.

PMID:
26161618
6.

Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.

Strömberg T, Feng X, Delforoush M, Berglund M, Lin Y, Axelson M, Larsson O, Georgii-Hemming P, Lennartsson J, Enblad G.

Med Oncol. 2015 Jul;32(7):188. doi: 10.1007/s12032-015-0630-y. Epub 2015 May 29.

PMID:
26021470
7.

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism.

Waraky A, Akopyan K, Parrow V, Strömberg T, Axelson M, Abrahmsén L, Lindqvist A, Larsson O, Aleem E.

Oncotarget. 2014 Sep 30;5(18):8379-92.

8.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 Nov 30;5(22):11193-208.

9.

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.

Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, Kufrin D, Palmby T, Dong Z, Russell AM, Miksinski S, Keegan P, Pazdur R.

Clin Cancer Res. 2013 May 1;19(9):2289-93. doi: 10.1158/1078-0432.CCR-12-1956. Epub 2013 Mar 20.

10.

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Österborg A, Atadja P, Larsson O, Axelson M, Van Camp B, Jernberg-Wiklund H, Vanderkerken K.

Clin Cancer Res. 2012 Apr 15;18(8):2230-9. doi: 10.1158/1078-0432.CCR-11-1764. Epub 2012 Mar 5.

11.

Cortisol metabolism after weight loss: associations with 11 β-HSD type 1 and markers of obesity in women.

Rask E, Simonyte K, Lönn L, Axelson M.

Clin Endocrinol (Oxf). 2013 May;78(5):700-5. doi: 10.1111/j.1365-2265.2012.04333.x.

PMID:
22233384
12.

Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications.

Feng X, Aleem E, Lin Y, Axelson M, Larsson O, Strömberg T.

Int J Oncol. 2012 Apr;40(4):1251-8. doi: 10.3892/ijo.2011.1281. Epub 2011 Dec 6.

13.
14.

Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).

Hashemi J, Worrall C, Vasilcanu D, Fryknäs M, Sulaiman L, Karimi M, Weng WH, Lui WO, Rudduck C, Axelson M, Jernberg-Wiklund H, Girnita L, Larsson O, Larsson C.

PLoS One. 2011 Mar 14;6(3):e14757. doi: 10.1371/journal.pone.0014757.

15.

Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry.

Rönquist-Nii Y, Eksborg S, Axelson M, Harmenberg J, Ekman S, Bergqvist M, Beck O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 15;879(5-6):326-34. doi: 10.1016/j.jchromb.2010.12.017. Epub 2010 Dec 28. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 15;889-890:148. Ekman, Simon [added]; Bergqvist, Michael [added].

PMID:
21251888
16.

Myostatin decreases with aerobic exercise and associates with insulin resistance.

Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE.

Med Sci Sports Exerc. 2010 Nov;42(11):2023-9. doi: 10.1249/MSS.0b013e3181e0b9a8.

17.

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.

Yin S, Girnita A, Strömberg T, Khan Z, Andersson S, Zheng H, Ericsson C, Axelson M, Nistér M, Larsson O, Ekström TJ, Girnita L.

Neuro Oncol. 2010 Jan;12(1):19-27. doi: 10.1093/neuonc/nop008. Epub 2009 Oct 20.

18.

Selective insulin-like growth factor-I antagonist inhibits mouse embryo development in a dose-dependent manner.

Inzunza J, Danielsson O, Lalitkumar PG, Larsson O, Axelson M, Töhönen V, Danielsson KG, Stavreus-Evers A.

Fertil Steril. 2010 May 15;93(8):2621-6. doi: 10.1016/j.fertnstert.2009.12.044.

PMID:
20138270
19.

Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation.

Natalishvili N, Axelson M, Girnita L, Larsson O, Vasilcanu D.

Exp Cell Res. 2009 May 1;315(8):1458-67. doi: 10.1016/j.yexcr.2009.01.008. Epub 2009 Jan 23.

PMID:
19302825
20.

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.

Economou MA, Wu J, Vasilcanu D, Rosengren L, All-Ericsson C, van der Ploeg I, Menu E, Girnita L, Axelson M, Larsson O, Seregard S, Kvanta A.

Acta Ophthalmol. 2008 Nov;86 Thesis 4:42-9. doi: 10.1111/j.1755-3768.2008.01185.x.

21.

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O.

Acta Ophthalmol. 2008 Nov;86 Thesis 4:35-41. doi: 10.1111/j.1755-3768.2008.01184.x.

22.

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Girnita A, All-Ericsson C, Economou MA, Aström K, Axelson M, Seregard S, Larsson O, Girnita L.

Acta Ophthalmol. 2008 Nov;86 Thesis 4:26-34. doi: 10.1111/j.1755-3768.2008.01183.x.

23.

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.

Economou MA, Wu J, Vasilcanu D, Rosengren L, All-Ericsson C, van der Ploeg I, Menu E, Girnita L, Axelson M, Larsson O, Seregard S, Kvanta A.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2620-6. doi: 10.1167/iovs.07-0742.

PMID:
18515591
24.

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2337-42. doi: 10.1167/iovs.07-0819.

PMID:
18515579
25.

CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol--potential role(s) for estrogen signaling.

Pettersson H, Holmberg L, Axelson M, Norlin M.

FEBS J. 2008 Apr;275(8):1778-89. doi: 10.1111/j.1742-4658.2008.06336.x. Epub 2008 Mar 7.

26.

Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.

Törnkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B, Axelson M, Girnita L.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):793-800. doi: 10.1016/j.bbrc.2008.01.162. Epub 2008 Feb 11.

PMID:
18267106
27.

Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.

Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M, Girnita L.

Mol Pharmacol. 2008 Mar;73(3):930-9. Epub 2007 Dec 10.

PMID:
18070930
28.

Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: a consequence of heparin "flushes".

Refaai MA, Warkentin TE, Axelson M, Matevosyan K, Sarode R.

Thromb Haemost. 2007 Nov;98(5):1139-40. No abstract available.

PMID:
18000622
29.

Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.

Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L, Larsson O.

Oncogene. 2008 Mar 6;27(11):1629-38. Epub 2007 Sep 10.

PMID:
17828296
30.

The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling.

Razuvaev A, Henderson B, Girnita L, Larsson O, Axelson M, Hedin U, Roy J.

J Vasc Surg. 2007 Jul;46(1):108-15.

31.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

32.

Role of pituitary hormones on 17alpha-ethinylestradiol-induced cholestasis in rat.

Henríquez-Hernández LA, Flores-Morales A, Santana-Farré R, Axelson M, Nilsson P, Norstedt G, Fernández-Pérez L.

J Pharmacol Exp Ther. 2007 Feb;320(2):695-705. Epub 2006 Nov 15.

PMID:
17108234
33.

Insulin-like growth factor-I is an important antiapoptotic factor for rat leydig cells during postnatal development.

Colón E, Zaman F, Axelson M, Larsson O, Carlsson-Skwirut C, Svechnikov KV, Söder O.

Endocrinology. 2007 Jan;148(1):128-39. Epub 2006 Oct 5.

PMID:
17023532
34.

Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I.

Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, Savu O, Axelson M, Biberfeld P, Poellinger L, Brismar K.

Clin Cancer Res. 2006 Aug 1;12(15):4506-14.

35.

The liquorice effect on the RAAS differs between the genders.

Sigurjonsdottir HA, Axelson M, Johannsson G, Manhem K, Nyström E, Wallerstedt S.

Blood Press. 2006;15(3):169-72.

PMID:
16864159
36.

IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-).

Rosengren L, Vasilcanu D, Vasilcanu R, Fickenscher S, Sehat B, Natalishvili N, Naughton S, Yin S, Girnita A, Girnita L, Axelson M, Larsson O.

Biochem Biophys Res Commun. 2006 Sep 8;347(4):1059-66. Epub 2006 Jul 12.

PMID:
16857168
37.

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Girnita A, All-Ericsson C, Economou MA, Aström K, Axelson M, Seregard S, Larsson O, Girnita L.

Clin Cancer Res. 2006 Feb 15;12(4):1383-91.

38.

Liquorice in moderate doses does not affect sex steroid hormones of biological importance although the effect differs between the genders.

Sigurjonsdottir HA, Axelson M, Johannsson G, Manhem K, Nystrom E, Wallerstedt S.

Horm Res. 2006;65(2):106-10. Epub 2006 Feb 3.

PMID:
16462145
39.

The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection.

Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, Axelson M, Larsson O, Larsson C, Girnita L.

Oncogene. 2006 May 25;25(22):3186-95.

PMID:
16407828
40.

GH effect on enzyme activity of 11betaHSD in abdominal obesity is dependent on treatment duration.

Sigurjónsdóttir HA, Koranyi J, Axelson M, Bengtsson BA, Johannsson G.

Eur J Endocrinol. 2006 Jan;154(1):69-74.

PMID:
16381993
41.

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Osterborg A, Vanderkerken K, Nilsson K, Jernberg-Wiklund H.

Blood. 2006 Jan 15;107(2):669-78. Epub 2005 Sep 15.

PMID:
16166596
42.

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, Van Camp B, Vanderkerken K.

Blood. 2006 Jan 15;107(2):655-60. Epub 2005 Jul 26. Erratum in: Blood. 2011 Mar 24;117(12):3476.

PMID:
16046527
43.

Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach.

Ulfarsson E, Karström A, Yin S, Girnita A, Vasilcanu D, Thoren M, Kratz G, Hillman J, Axelson M, Larsson O, Girnita L.

Clin Cancer Res. 2005 Jul 1;11(13):4674-80.

44.

A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.

Rodriguez-Antona C, Axelson M, Otter C, Rane A, Ingelman-Sundberg M.

J Biol Chem. 2005 Aug 5;280(31):28324-31. Epub 2005 Jun 2.

45.

Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival.

Catrina SB, Lewitt M, Massambu C, Dricu A, Grünler J, Axelson M, Biberfeld P, Brismar K.

Br J Cancer. 2005 Apr 25;92(8):1467-74.

47.

Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men.

Lütjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K, Reichel C.

Int J Clin Pharmacol Ther. 2004 Jun;42(6):307-13.

PMID:
15222722
48.

Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia.

Weinbrenner T, Züger M, Jacoby GE, Herpertz S, Liedtke R, Sudhop T, Gouni-Berthold I, Axelson M, Berthold HK.

Br J Nutr. 2004 Jun;91(6):959-69.

PMID:
15182399
49.

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M.

Cancer Res. 2004 Jan 1;64(1):236-42.

50.

Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor.

Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thörne A, Nowak G, Ericzon BG, Björkhem I, Einarsson C.

Hepatology. 2003 Oct;38(4):930-8.

PMID:
14512880

Supplemental Content

Loading ...
Support Center